Pfizer (NYSE:PFE) has been one of the Dow's worst performers over the past two months. Since Aug. 1, shares of the Big Pharma giant are down 9%, and sentiment appears to be even more bearish now that the company has decided not to split up.
The company had been considering breaking itself up into two separately-traded entities, which would have been called Pfizer Innovative Health and Pfizer Essential Health. The rationale for the move was that both pieces trading independently could have collectively received a higher valuation than the single entity does today.
